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THE abnormal protein-bound polysaccharide associated with multiple myeloma
(Sachs, Cady and Ross, 1954) and the handling of radiosulfate by patients with
this disorder (Siegel, Sachs and Graig, 1959) have been reported previously. The
present study describes the fate of 35S labelled cystine in myeloma anid other
malignant neoplasms, and compares these results with those published earlier
for radiosulfate.
MATERIALS AND METHODS
35S as 1-cystine (specific activity of about 30 mc/g.) in doses of approximately
0* 5 mc was administered intravenously to 5 patients with multiple myeloma and
to 5 patients with other neoplastic diseases (Table I). The assays of radioactivity
were performed with a gas flow counter, since 35S is a pure, weak beta emitter
(0.168 mev maximum energy; 87 days half-life). Appropriate corrections for
self-absorption and back-scattering were made for the specimen geometry em-
ployed as well as for physical decay. The detectors used were calibrated against
35S standard solutions furnished by the National Bureau of Standards. Blood
was collected by venipuncture at intervals of 5 minutes, 1 hour, 4 hours, 8 hours,
24 hours, 2 days, 3 days, 5 days, 7 days, and 14 days following administration of
the tagged cystine. Blood specimens (about 15 ml.) were placed in test tubes
containing two drops of versene to prevent coagulation. Urine was collected for
the first 8 hours, the next 16 hours, and daily thereafter for two weeks after
injection of 35S cystine.
Calculations.-The 35S concentration (per cent dose/liter) in whole blood and
plasma (Fig. 1) and the fraction of the 35S dose excreted (per cent dose excreted)
in urine during 14 days following administration of the radioisotope were com-
puted (Table I and Fig. 2). The apparent space of dilution was calculated from
these blood and plasma data. This computation inivolved finding the hypothetical
concentration at zero-time by means ofgraphical extrapolation in order to obtain
the so-called zero-time radiosulfate space (Ryan et al., 1956). The ratios of space
to body weight and body surface were determined. Body surface of eachl subject
was obtained from the patient's weight and height using the conventionial Duii Bois
relationship.
RESULTS
35S blood levels. 35S in whole blood, as well as in plasma, falls rapidly for the
first 8 hours and then declines slowly (Fig. 1). This pattern is found in both mul-
tiple myeloma patients and the othel subjects. Since the levels and patterniis are35S-CYSTINE IN MULTIPLE MYELOMA 731
almost identical in whole blood and in plasma, only whole blood data are given
in Fig. 1. For whole blood, the initial maxima, obtained 5 minutes following
the injection of tagged cystine, range from 9.39 per cent dose/liter to 16-9 per
cent dose/liter for the myeloma patients and from 7.53 per cent dose/liter to
15.8 per cent dose/liter for the other group. At the same time, the corresponding
plasma concentrations range from 8*96 per cent dose/liter to 17.1 per cent dose/
liter for those with multiple myeloma and from 7*62 per cent dose/liter to 16.6
per cent dose/liter for the others. By 8 hours, these concentrations have dropped
to about one-third of their respective 5 minute peaks. These levels decrease
slowly thereafter, being about three-quarters of the 8 hour values at 5 days after
the administration of the tagged cystine.
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FIG. 1. The variation of the mnean 35S whole blood concentration with time for five patients with multiple myeloma and five patients with other malignant neoplasmns. The range (maximum and minimum values) is indicated by vertical lines extending from the individual
points.
By graphing the logarithm of whole blood and plasma 35S concentration
against time, it was found that the curves thus obtained could be resolved into
exponential components. The curves from three offive multiple myeloma patients
have two decay rates. An initial rapid decrease, corresponding to a half-disappear-
ance time (T1) of about 0-45 hour characterizes the fall of 35S during the first
hour. The decline thereafter is quite slow, described by a half-disappearance time
(T3) ofabout 280 hours (Fig. 2). An intermediate half-time (T2) ofabout 2.5 hours,
however, was present for the other two myeloma patients during the 1 to 8 hour
interval following the injection of the doses. For the other group of patients,
three distinct rates governed the disappearance ofthe 35S (Fig. 3). An initial half-
time (T1) of about 0.26 hour for the first hour is followed for the next 8 hours by
an intermediate component (T2) of about 1.4 hours. For the ensuing period, the
gradual fall is described by a half-time (T3) of about 160 hours. Mean values of732 E. SIEGEL, B. A. SACHS AND F. A. GRAIG
these half-disappearance times for both groups of patients, as derived from their
respective whole blood and plasma curves, based on the data collected over a
two week period, are listed in Table II. The figures reproduced here (Fig. 1 and 2)
cover only the initial 24 hours following the administration of the labeled amino
acid to illustrate more clearly the early phases.
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FIG. 2.-Resolution of the whole blood 35S concentration curve obtained fromi a patient with
multiple myeloma into two exponential components. T1 and T3 are the respective initial
and late half-disappearance times. The various half-disappearance times given in the figures
and Table II are actually based on graphs covering the two week period ofobservation; for
illustrative purposes, only the early values are presented here.
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FIG. 3. Resolution of the whole blood 35S concentration curve obtained from apatientwith a
malignant neoplasm other than multiple myeloma into three exponential components.
T1, T2 and T3 are the corresponding initial, intermediate and late half-disappearance times.35S-CYSTINE IN MULTIPLE MYELOMA
35S urinary excretion. The 35S excretion in the urine is relatively slow and
about the same for both groups of patients (Table I). The output of the first day
ranges from about 5 per cent of the dose to a maximum of about 20 per cent of
the dose. From the second day on, the 35S is eliminated in the urine exponentially
the average doubling-time for cumulative excretion being about 7.2 days (Fig. 4)
By the end of the first week, about 30 per cent of the dose has been excreted.
35S-cystine spaces of dilution. The zero-time radiosulfate whole blood spaces
and their respective ratios to body surface and to weight are given in Table I.
These results are similar for both the myeloma patients and those having other
neoplasms. The average space for patients with myeloma is 7.39 ± 1.41 liters,
corresponding to 13.2 ± 3.49 x 10-2 liter per kilogram of body weight. For the
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FIG. 4. The cumulative miean 35S urinary excretion for the first week following the adminis-
tration of the tagged cystine.
other patients, an average space of 8.66 i 2.67 liters or 14.7 ± 4.04 x 10-2 liter
per kilogram of body weight was found. As was noted earlier, since the 35S con-
centration in the whole blood and plasma are almost identical, the respective
spaces are likewise very similar, and, for brevity, only the whole blood radio-
sulfate spaces are tabulated.
DISCUSSION
The intravenous administration of 35S-1-cystine provides an immediate supply
of this readily detected labeled amino acid to all sites of protein synthesis. The
35S labeled cystine exchanges its labeled position with the other amino acids only
slightly, if at all. The sulfur of 35S-cystine is not transferred to methionine. It is
believed that through the use of this amino acid the uptake and loss of isotope
by the protein are almost exclusively in the form of the administered amino acid
(Goldsworthy and Volwiler, 1957). The resulting turnover curve is usually divided
into the following phases (Armstrong, Bronsky and Hershman, 1955; Golds-
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worthy and Volwiler, 1957): (a) rapid incorporation of the amino acid radio-
activity into the protein and rapid release of the newly synthesized protein into
the circulation in the first 24 hours; (b) the distribution and mixing period,
lasting a few days; (c) the exponential portion of the curve, presumed to reflect
primarily the rate of metabolic degradation of the labeled protein; and (d), if
the experiment continues for sufficient time, a phase reflecting the re-incorporation
ofthe isotope into the protein.
In comparing the fate of tagged cystine with that of radiosulfate, some sig-
nificant differences are observed. While the spaces of dilution for these two sub-
stances are quite similar and in accord with those reported for radiosulfate for
normal subjects as well as for others having malignancies (Siegel et al., 1959;
Ryan et al., 1956; Walser, Seldin and Grollman, 1953), the handling and turn-
over of these compounds are quite different. Fig. 1 illustrates the 35S whole blood
concentration as a function of time for those receiving labeled cystine. Following
administration of labeled cystine the 35S blood concentration decreases slowly;
thus, by the second day, when the 35S concentration following radiosulfate, as
previously reported by us, is less than 0.5 per cent dose/liter, the 35S concentration
from cystine is about six times greater. This markedly slow fall in 35S blood levels
is characterized by the greatly prolonged late (T3) half-disappearance times
following labeled cystine (Table II) as compared to those found for radiosulfate.
TABLE II.-Initial, Intermediate, and Late Half-disappearance Times
obtainedfrom 35S Whole Blood and Plasma Concentration Curves.
Average half-disappearance times (hours)
r-
Patients T1 T2 T3
Multiple myeloma . 0.448 ± 0.157* - t 281 i 77
Other neoplasms . 0.265 ± 0.135 1.41 ± 0.65 162 121
* Standard deviation.
t T2 was found in two of the five multiple myeloma patients, aver-
aging 2 -47 hours.
Thus, the average value T3 for patients with myeloma given 35S-cystine is 281
hours as compared to 15-9 hours following tagged sulfate. A similar lengthening
of this parameter is observed also for the patients with other neoplasms. There is
a corresponding lower output of 35S in the urine from 35S-cystine as compared to
that following administration of radiosulfate (Fig. 4). By the second day, when
more than 60 per cent of the injected sulfate has been excreted, those given 35S-
cystine have excreted only about 20 per cent of the dose. Furthermore, for those
given labeled cystine, an equilibrium is attained after the second day, the cumu-
lative urinary output growing exponentially, with an average doubling-time, as
noted earlier, of about 173 hours, which is in good agreement with the observed
late half-disappearance times (Table II). Thus, after the second day, the con-
stant fraction of the remaining dose, which disappears daily from the blood, was
found in the urine, suggesting that the 35S is then being degraded and directly
excreted.
When 35S-cystine is administered to control subjects, the label is incorporated
into the normal serum albumin andglobulins. When35S-cystine isgiventopatients
with myeloma, the label also is incorporated into the normal albumin and globulins
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as well as the abnormal myeloma globulins. The present investigation did not
inivolve study of homologous serum proteins, and the curves obtained represent
summation effects for all the serum protein complexes. It is possible that if
individual globulins were studied, greater differences might have been observed
between the turnover of the 35S-cystine labeled normal globulins and the labeled
myeloma globulins (Putnam, 1959).
There is a suggestive finding of a difference in the fate of 35S-cystine for
myeloma patients as compared to those having other malignancies. The initial
(T1) and late (T3) half-disappearance times are longer for those having myeloma
(Table II). This suggests that the hyperglobulinemia ofmyeloma may result from
a slower catabolism of myeloma globulin. In this connection, Putnam and Hardy
(1955) observed a greater half-disappearance time for the turnover of beta mye-
loma globulin than that obtained for the normal beta globulins by London (1950),
and stated that the hyperglobulinemia of myeloma might be due to accumulation
of the myeloma globulin by virtue of its slow turnover rate.
SUMMARY
35S-l-cystine (specific activity 30 mc/g.) in doses of approximately 0.5 mc was
administered intravenously to five patients with multiple myeloma and to five
subjects with other neoplastic diseases. For both groups of patients, the 35S con-
centration of whole blood and plasma were similar. The 35S blood levels declined
slowly; at five days after administration of the dose they were approximately
three-quarters of the initial 8 hour values. The mean zero-time spaces of dilution
were 7.39 ± 1.41 liters for the patients with multiple myeloma and 8-66 ± 2.67
liters for those with other neoplasms. 35S urinary excretion was low, 13.6 to 30-9
per cent of the dose appearing in the urine within 72 hours. The turnover and
excretion of 35S administered as cystine are very much slower than when given
as radiosulfate. By graphical analysis, it was possible to resolve the blood con-
centration curves into three exponential components. Patients with multiple
myeloma were found to have longer initial and late half-disappearance times
when compared to the subjects with other neoplastic diseases.
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